Overture Life, the biotechnology company credited with developing the world’s first babies born from robotic fertilization and robotic egg freezing, has officially opened its first U.S. clinical facility at 4621 Ross Avenue in The Bogart Building, Dallas. The new site will serve as the company’s U.S. operations headquarters and is dedicated to advancing AI-powered IVF robotics and non-invasive embryo testing.

The Dallas laboratory will run CLIA-licensed, non-invasive embryo-assessment tests that analyze molecular activity in the fluid surrounding embryos, a process known as metabolomics, supported by machine learning. This innovation offers fertility teams objective, biopsy-free insights to guide embryo selection and treatment. The establishment of the Dallas hub marks a strategic step for Overture Life, bridging its European manufacturing and research base with the growing North American fertility technology market.

“This Dallas hub bridges our European manufacturing and research operations with North American markets,” said Hans Gangeskar, CEO of Overture Life. “The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.”

The Old East Dallas facility will anchor Overture’s expansion across the United States, particularly as interest in its DaVitri automated egg-freezing system continues to rise. The platform, a hallmark of AI-powered IVF robotics, uses robotic precision to freeze eggs, achieving a 12% increase in egg survival rates and allowing clinics to handle up to three times the usual number of procedures without increasing staff.

Hafsa Irfan, Head of Clinical Operations at the Dallas site, will lead the scientific build-out and oversee assay optimization and laboratory operations. “The infrastructure we're establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,” Irfan said.

Representing a multi-million-dollar investment, the facility has been designed to accommodate advanced laboratory capabilities and scalable automation protocols. The lab’s infrastructure will also support continuous learning AI systems to ensure the reproducibility, measurement, and clinical validation of AI-powered IVF robotics in real-world fertility treatment.

Dallas was selected for its strong biomedical ecosystem, with more than 27,000 professionals across 850 companies working in life sciences, medical devices, and clinical research. The city’s proximity to major research institutions, including UT Southwestern Medical Center, further reinforces its role as a growing hub for reproductive technology innovation.

Overture Life’s automation platforms address the most technically challenging procedures in IVF. The company’s ICSI. A system made history in 2024 with the world’s first robotic sperm injection leading to successful births. Its DaVitri system standardizes the egg-freezing process, a task that previously required years of expert training, allowing embryologists to achieve consistent results while reducing manual workload.

The company plans to hire across product development, clinical operations, manufacturing, regulatory affairs, quality assurance, and commercial roles at the Dallas facility. The site will also work closely with Overture’s research teams in Spain and its network of international clinical partners.

The Dallas hub joins Overture’s European laboratories as the company builds the infrastructure needed to meet rising demand for AI-powered IVF robotics and automated embryo testing worldwide. The DaVitri system’s European pre-order list, launched in September, filled within weeks as fertility clinics sought proven automation systems backed by peer-reviewed results and healthy birth outcomes.